FDA Approves Pediatric Indication for Xeomin (incobotulinumtoxina) for the Treatment of Chronic Sialorrhea

RALEIGH, N.C., December 21, 2020 -- Merz Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Xeomin (incobotulinumtoxinA) for the treatment of...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news